Aridol Kit is a drug owned by Pharmaxis Europe Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 23, 2015. Details of Aridol Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5817028 | Method and device for the provocation of air passage narrowing and/or the induction of sputum |
Feb, 2015
(9 years ago) |
Expired
|
FDA has granted several exclusivities to Aridol Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Aridol Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Aridol Kit.
Exclusivity Information
Aridol Kit holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Aridol Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 05, 2013 |
US patents provide insights into the exclusivity only within the United States, but Aridol Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aridol Kit's family patents as well as insights into ongoing legal events on those patents.
Aridol Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aridol Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 23, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aridol Kit Generic API suppliers:
Mannitol is the generic name for the brand Aridol Kit. 6 different companies have already filed for the generic of Aridol Kit, with Igi Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Aridol Kit's generic
About Aridol Kit
Aridol Kit is a drug owned by Pharmaxis Europe Ltd. It is used for assessing bronchial hyperresponsiveness in patients over 6 years old without clinically apparent asthma. Aridol Kit uses Mannitol as an active ingredient. Aridol Kit was launched by Pharmaxis Europe in 2010.
Approval Date:
Aridol Kit was approved by FDA for market use on 05 October, 2010.
Active Ingredient:
Aridol Kit uses Mannitol as the active ingredient. Check out other Drugs and Companies using Mannitol ingredient
Treatment:
Aridol Kit is used for assessing bronchial hyperresponsiveness in patients over 6 years old without clinically apparent asthma.
Dosage:
Aridol Kit is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A,5MG,10MG,20MG,40MG | POWDER | Prescription | INHALATION |